Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 2.77 MB, PDF document
The majority of neoantigens arise from unique mutations that are not shared between individual patients, making neoantigen-directed immunotherapy a fully personalized treatment approach. Novel technical advances in next-generation sequencing of tumor samples and artificial intelligence (AI) allow fast and systematic prediction of tumor neoantigens. This study investigates feasibility, safety, immunity, and anti-tumor potential of the personalized peptide-based neoantigen vaccine, EVX-01, including the novel CD8(+) T-cell inducing adjuvant, CAF (R) 09b, in patients with metastatic melanoma (NTC03715985). The AI platform PIONEERTM was used for identification of tumor-derived neoantigens to be included in a peptide-based personalized therapeutic cancer vaccine. EVX-01 immunotherapy consisted of 6 administrations with 5-10 PIONEERTM-predicted neoantigens as synthetic peptides combined with the novel liposome-based Cationic Adjuvant Formulation 09b (CAF (R) 09b) to strengthen T-cell responses. EVX-01 was combined with immune checkpoint inhibitors to augment the activity of EVX-01-induced immune responses. The primary endpoint was safety, exploratory endpoints included feasibility, immunologic and objective responses. This interim analysis reports the results from the first dose-level cohort of five patients. We documented a short vaccine manufacturing time of 48-55 days which enabled the initiation of EVX-01 treatment within 60 days from baseline biopsy. No severe adverse events were observed. EVX-01 elicited long-lasting EVX-01-specific T-cell responses in all patients. Competitive manufacturing time was demonstrated. EVX-01 was shown to be safe and able to elicit immune responses targeting tumor neoantigens with encouraging early indications of a clinical and meaningful antitumor efficacy, warranting further study.
Original language | English |
---|---|
Article number | 2023255 |
Journal | OncoImmunology |
Volume | 11 |
Issue number | 1 |
Number of pages | 15 |
ISSN | 2162-402X |
DOIs | |
Publication status | Published - 31 Dec 2022 |
- Personalized therapy, neoantigen, immune response, cancer vaccine, immunotherapy, T-CELL RESPONSES, CANCER, CAF09, ANTI-PD-1, BLOCKADE, IMMUNITY, AVIDITY, FUTURE
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 315400246